Product logins

Find logins to all Clarivate products below.


Global Consequences of Smoking Cessation: NSCLC Incidence over the Next Two Decades

The strongest risk factor that drives change in the incidence of non-small-cell lung cancer (NSCLC) is the historical prevalence of smoking. The long lag between the initiation of tobacco use and the development of lung cancer is an indicator that we have only seen the tip of the iceberg regarding long-term effects of the smoking epidemic. This finding is compounded by the effect of population aging and growth. Owing to the shift in disease risk, we do not use historical NSCLC incidence to predict future incidence of NSCLC. Changing patterns in risk, based on evolving smoking patterns, following increased awareness and investment in tobacco control strategies need to be incorporated in forecasting NSCLC incidence.

Related Market Assessment Reports

Report
Non-Small-Cell Lung Cancer | China In-Depth | China | 2025
Non-small-cell lung cancer (NSCLC) is the leading cause of cancer-related mortality in China. Treatment is based on biomarker status; patients with EGFR- and ALK-positive tumors generally receive…
Report
Small Cell Lung Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)
The treatment landscape for small-cell lung cancer (SCLC) has seen significant advances in the past few years. Previously, chemotherapy and radiotherapy were the predominant treatments, but…
Report
Non-Small-Cell Lung Cancer | Disease Landscape & Forecast | G7 | 2025
The multibillion-dollar NSCLC therapy market is highly dynamic, with a plethora of approved therapies but still a high unmet need. Immune checkpoint inhibitors such as Keytruda (Merck & Co.)…
Report
Non-Small-Cell Lung Cancer | Current Treatment: Physician Insights | US | May 2025
Immune checkpoint inhibitors continue to dominate the treatment of non-small-cell lung cancer (NSCLC), while biomarker-based approaches are driving increasing patient segmentation. In 2024, Imfinzi…
Report
Non-Small-Cell Lung Cancer | Treatment Sequencing | US | 2025
Key benefits and uses Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand who to position…